Merus NV
MRUS90.000USD
0.0000.00%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
6.83BCap. mercado
PérdidaP/E TTM
Más Datos de Merus NV Compañía
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.
Información de Merus NV
Símbolo de cotizaciónMRUS
Nombre de la empresaMerus NV
Fecha de salida a bolsaMay 19, 2016
Director ejecutivoLundberg (Sven Ante)
Número de empleados260
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 19
DirecciónYalelaan 62
CiudadUTRECHT
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísNetherlands
Código postal3584 CM
Teléfono310302538800
Sitio Webhttps://merus.nl/
Símbolo de cotizaciónMRUS
Fecha de salida a bolsaMay 19, 2016
Director ejecutivoLundberg (Sven Ante)
Ejecutivos de Merus NV
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
168.44K
-30297.00%
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Peter B. Silverman, J.D.
Mr. Peter B. Silverman, J.D.
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
--
--
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Gregory D. (Greg) Perry
Mr. Gregory D. (Greg) Perry
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Leonard (Len) Kanavy
Mr. Leonard (Len) Kanavy
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Paolo Pucci
Mr. Paolo Pucci
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sherri Spear
Ms. Sherri Spear
Investor Relations and Corporate Communications
Investor Relations and Corporate Communications
--
--
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
168.44K
-30297.00%
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Peter B. Silverman, J.D.
Mr. Peter B. Silverman, J.D.
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
--
--
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Gregory D. (Greg) Perry
Mr. Gregory D. (Greg) Perry
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Leonard (Len) Kanavy
Mr. Leonard (Len) Kanavy
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: sáb., 3 de ene
Actualizado: sáb., 3 de ene
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Paradigm BioCapital Advisors LP
5.77%
Avoro Capital Advisors LLC
4.67%
Commodore Capital LP
4.65%
Deerfield Management Company, L.P.
4.02%
HBK Investments, L.P.
3.76%
Otro
77.14%
Accionistas
Accionistas
Proporción
Paradigm BioCapital Advisors LP
5.77%
Avoro Capital Advisors LLC
4.67%
Commodore Capital LP
4.65%
Deerfield Management Company, L.P.
4.02%
HBK Investments, L.P.
3.76%
Otro
77.14%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
39.38%
Investment Advisor/Hedge Fund
27.56%
Investment Advisor
13.49%
Research Firm
2.54%
Corporation
1.93%
Private Equity
1.78%
Venture Capital
1.47%
Pension Fund
0.56%
Bank and Trust
0.49%
Otro
10.81%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
498
69.89M
92.15%
-15.18M
2025Q3
434
77.32M
101.98%
-5.60M
2025Q2
411
75.46M
99.77%
-10.50M
2025Q1
420
74.82M
101.12%
-10.15M
2024Q4
398
74.69M
108.18%
-7.45M
2024Q3
373
72.99M
107.03%
-6.71M
2024Q2
355
69.91M
103.77%
+7.77M
2024Q1
315
57.35M
97.63%
-5.32M
2023Q4
282
57.36M
99.41%
-5.55M
2023Q3
268
57.60M
100.50%
+2.76M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Paradigm BioCapital Advisors LP
4.37M
5.77%
+91.82K
+2.14%
Sep 30, 2025
Avoro Capital Advisors LLC
3.54M
4.67%
+386.94K
+12.26%
Sep 30, 2025
Commodore Capital LP
3.52M
4.65%
--
--
Sep 30, 2025
Deerfield Management Company, L.P.
3.05M
4.02%
-337.71K
-9.98%
Sep 30, 2025
HBK Investments, L.P.
2.85M
3.76%
+2.85M
--
Sep 30, 2025
Westfield Capital Management Company, L.P.
2.13M
2.81%
+90.10K
+4.41%
Sep 30, 2025
RTW Investments L.P.
2.03M
2.67%
-1.98M
-49.38%
Sep 30, 2025
Fidelity Management & Research Company LLC
1.94M
2.55%
-4.28M
-68.87%
Sep 30, 2025
Woodline Partners LP
1.67M
2.21%
+131.27K
+8.51%
Sep 30, 2025
Glazer Capital, LLC
1.62M
2.13%
+1.62M
--
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: mar., 2 de dic
Actualizado: mar., 2 de dic
Nombre
Proporción
AltShares Merger Arbitrage ETF
3.3%
NYLI Merger Arbitrage ETF
3.1%
ALPS Medical Breakthroughs ETF
2.89%
Goldman Sachs Hedge Industry VIP ETF
2.75%
ProShares Merger ETF
2.74%
First Trust IPOX Europe Equity Opportunities ETF
2.61%
Tema Oncology ETF
2.61%
Invesco Dorsey Wright Healthcare Momentum ETF
1.4%
Harbor Health Care ETF
1.29%
AltShares Event-Driven ETF
1.23%
Ver más
AltShares Merger Arbitrage ETF
Proporción3.3%
NYLI Merger Arbitrage ETF
Proporción3.1%
ALPS Medical Breakthroughs ETF
Proporción2.89%
Goldman Sachs Hedge Industry VIP ETF
Proporción2.75%
ProShares Merger ETF
Proporción2.74%
First Trust IPOX Europe Equity Opportunities ETF
Proporción2.61%
Tema Oncology ETF
Proporción2.61%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporción1.4%
Harbor Health Care ETF
Proporción1.29%
AltShares Event-Driven ETF
Proporción1.23%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
